Howmanypatents

Sign in Subscribe

Latest — Dec 9, 2025

Abbott to Acquire Exact Sciences for US$21 Billion — What the Patent Portfolio Reveals

Abbott’s US$21 billion acquisition of Exact Sciences is one of the largest diagnostics deals in recent years. A closer look at Exact Sciences’ patent portfolio offers insight into the technical depth behind the transaction. Abbott and Exact Sciences confirm acquisition deal On 20th November 2025, Abbott and Exact

More issues

Is Pictiva’s US$191 million win proof of enduring OLED innovation — or of effective IP monetisation?

On 4th November 2025, a Texas jury found that Samsung Electronics had infringed two US OLED patents owned by Pictiva Displays International, a subsidiary of Key Patent Innovations, which invests in and licenses high-value patent portfolios in emerging technology markets. The Federal Court ordered Samsung to pay US$191.4

Hologic to be acquired by private equity

Hologic, Inc., announced on 21 October 2025 that it has entered into a definitive agreement to be acquired by funds managed by Blackstone and TPG in a transaction valued at up to US$79 per share, representing an enterprise value of up to US$18.3 billion. Under the terms

Quantum Technology Companies: patent analysis - part III

Background: Quantum computing patent applications have increased significantly since 2009, reflecting the growing maturity and industrial relevance of the field. Patent intelligence for people who don't read patents However, for those without a background in patents, or the means to access patent analytics, it’s not always clear

Quantum Technology Companies: patent analysis - part II

Background: Quantum computing patent applications have increased significantly since 2009, reflecting the growing maturity and industrial relevance of the field. Patent intelligence for people who don't read patents However, for those without a background in patents, or the means to access patent analytics, it’s not always clear

Quantum Technology Companies: patent analysis

Quantum computing patent applications have increased significantly since 2009, reflecting the growing maturity and industrial relevance of the field. Patent intelligence for people who don't read patents However, for those without a background in patents, or the means to access patent analytics, it’s not always clear what

Illumina's acquisition of Somalogic is a clear IP play

Illumina announced on 23 June 2025 that it will acquire SomaLogic from Standard BioTools, for US$350 million cash plus up to US$75 million in performance-based payments, reinforcing its multiomics roadmap by embedding high-plex proteomics into its sequencing operations. The transaction, expected to close in the first half of

Lilly hedges IP risk in $1.3bn Verve acquisition

Eli Lilly has announced its intention to acquire Verve Therapeutics for approximately US$1.3 billion, aiming to accelerate development of one-time gene-editing treatments for cardiovascular disease. The acquisition builds on a pre-existing collaboration between the two companies focused on in vivo gene editing and positions Lilly to compete more

IonQ to acquire Oxford Ionics: IP play, market access—or something more?

IonQ and Oxford Ionics have announced they have entered into a definitive agreement for IonQ to acquire Oxford Ionics in a transaction valued at US$1.075 billion, which will consist of US$1.065 billion in shares of IonQ common stock and approximately US$10 million in cash (subject

Regeneron acquires 23andMe to access DNA profiling IP

Regeneron Inc has announced it has entered into an Asset Purchase Agreement to acquire 23andMe for US$ 256 Million. The planned purchase aims to strengthen Regeneron’s ongoing leadership in genetics-guided research and drug development to help people with serious diseases. Regeneron has stated that it plans to: * maintain the